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Objectives: To assess the impact of atopy and allergy
on the risk of clinical malaria.
Design: A clinical and immunological allergy cross-
sectional survey in a birth cohort of 175 children from
1 month to 14 years of age followed for up to 15 years
in a longitudinal open cohort study of malaria in
Senegal. Malaria incidence data were available for 143
of these children (aged 4 months to 14 years of age)
for up to 15 years. Mixed-model regression analysis
was used to determine the impact of allergy status on
malaria incidence, adjusting for age, gender, sickle-cell
trait and force of infection.
Main outcome measures: Asthma, allergic
rhinoconjunctivitis and atopic dermatitis status, the
number of clinical Plasmodium falciparum malaria
episodes since birth and associated parasite density.
Results: 12% of the children were classified as
asthmatic and 10% as having atopic dermatitis. These
groups had respectively a twofold (OR 2.12 95%; CI
1.46 to 3.08; p=8×10−5) and threefold (OR 3.15; 1.56
to 6.33; p=1.3×10−3) increase in the risk of clinical
P falciparum malaria once older than the age of peak
incidence of clinical malaria (3–4 years of age). They
also presented with higher P falciparum parasite
densities (asthma: mean 105.3 parasites/μL±SE 41.0
vs 51.3±9.7; p=6.2×10−3. Atopic dermatitis: 135.4
±70.7 vs 52.3±11.0; p=0.014). There was no effect of
allergy on the number of non-malaria clinical
presentations. Individuals with allergic
rhinoconjunctivitis did not have an increased risk of
clinical malaria nor any difference in parasite
densities.
Conclusions: These results demonstrate that
asthma and atopic dermatitis delay the development of
clinical immunity to P falciparum. Despite the
encouraging decrease in malaria incidence rates in
Africa, a significant concern is the extent to which the
increase in allergy will exacerbate the burden of
malaria. Given the demonstrated antiparasitic effect of
antihistamines, administration to atopic children will
likely reduce the burden of clinical malaria in these
children, increase the efficacy of first-line treatment
antimalarials and alleviate the non-infectious
consequences of atopy.
INTRODUCTION
The World Allergy Organisation estimates
that 40% of the world’s population is con-
cerned by allergic diseases.1 In developing
countries where Plasmodium falciparum
malaria is endemic, prevalence of allergy is
significantly lower, but is on the increase.2
T helper type 2 (Th2) cells, their related
cytokines, IgE, eosinophils and mast cells
(MCs) play a major role in allergic inflamma-
tion. Orientation of the immune response
towards a Th1 profile is crucial for immunity
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length of time. The major weakness of the study
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to intracellular pathogens,3 whereas orientation towards
a Th2 profile drives immunity to extracellular pathogens
and antigens resulting in class switching giving rise to
IgE-producing B cells.4 A role of the Th1/Th2 balance
in the development of clinical malaria following infec-
tion by P falciparum has been suggested by numerous
studies.5–7 While it is recognised that acquired antipara-
site immunity is IgG dependent,8 parasite-specific IgE
also impact upon the clinical outcome of infection. For
example, higher IgE but not IgG levels have been
observed in patients with cerebral malaria than those
with uncomplicated P falciparum infection.9 The role of
IgE, however, remains unclear.10
The interplay between infectious agents and allergy is
ambiguous. On the one hand, for example, severe
respiratory syncytial virus infection in infants increased
the risk of allergic rhinoconjunctivitis and allergic
asthma.11 12 On the other hand, measles,13 hepatitis A14
and tuberculosis15 seemingly reduce atopy. Although, an
atopic condition can increase incidence of disease, such
as the case for the skin commensal Staphylococcus aureus
in patients with atopic dermatitis,16 an atopic tendency
per se does not generally lead to increased illness from
infectious agents.
Genome-wide studies have identified chromosomal
regions linked to clinical malaria, all of which overlap
with those previously identified to be involved in atopic
dermatitis, asthma, atopy and IgE levels,17–19 suggesting
that common mechanisms may be involved in both path-
ologies.20 Chromosomal region 5q31 that has been
repeatedly shown to be associated with control of para-
site density and contains a cluster of cytokines, among
which IL12B has been previously associated with psoria-
sis.21 The other regions, 13q13–q22, 5p15–p13 and
12q21–q23, contain genes involved in innate immunity,
notably the interleukin 7 receptor, and several involved
in tumour necrosis factor synthesis (C1q and tumour
necrosis factor-related protein 3 (C1QTNF3)) and a
gene involved in the complement system (C9).20
Several additional lines of evidence support the
concept that susceptibility to malaria and atopy may be
related to similar immunological defects. In Ethiopia, a
history of malaria was associated with atopy.22 A mouse
model for human atopic disease was found to be very
susceptible to murine malaria and a major locus for
atopic disease mapped close to the region controlling
parasite density.23 This region contains several candidate
genes that have effects on T cell function.23
Moreover, a direct effect of histamine in the malaria
pathogenesis has been found using genetic and pharma-
cological approaches24 and increased levels of histamine
are associated with the severity of disease in humans
infected with P falciparum and in animal malaria
models.25 26
To test the hypothesis that allergy impacts upon clin-
ical P falciparum malaria, we performed a clinical allergy
cross-sectional study in the family-based longitudinal
cohort from Senegal previously used for the genome
linkage study20 and analysed the impact of asthma,
atopic dermatitis, allergic rhinoconjunctivitis on the inci-
dence of clinical P falciparum episodes and the
maximum parasite density during each episode.
METHODS
Population and outcome data
The malaria research programme conducted in Dielmo
village in Senegal has been ongoing since 1990 as
described elsewhere.27 In brief, between 1990 and 2008, a
longitudinal study involving the inhabitants of the village
of Dielmo, Senegal, was carried out to identify all episodes
of fever. The study design included daily medical surveil-
lance with systematic blood testing of individuals with fever
and examination of 200 oil-immersion fields on a thick
blood film for malaria parasites (about 0.5 μL of blood).
Each individual was given a unique identification code
and details of family ties, occupation and precise place of
residence were recorded on detailed maps of each house-
hold with the location of each bedroom. All households
were visited daily, absenteeism recorded and the presence
of fever or other symptoms assessed. We systematically
recorded body temperature at home three times a week
(every second day) in children younger than 5 years, and
in older children and adults in cases of suspected fever or
fever-related symptoms. In cases of fever or other symp-
toms, blood testing was carried out at the dispensary by
finger prick, and we provided detailed medical examin-
ation and specific treatment. Parasitologically confirmed
clinical malaria episodes were treated according to
national guidelines. From 1990 to 2008, four different
drug regimens were implemented: quinine from 1990 to
1994, chloroquine from 1995 to 2003, fansidar
(sulfadoxine-pyrimethamine) from 2004 to mid-2006 and
artemisinin-based combination therapy (Amodiaquine-
sulfadoxine-pyrimethamine; ACT) from mid-2006 to 2008.
Parasite positivity was established as follows. Thick
blood films were prepared and stained by 3% Giemsa
stain. Blood films were examined under an oil immer-
sion objective at ×1000 magnification by the trained
laboratory technicians and 200 thick film fields were
examined to count the number of asexual and gameto-
cyte parasite stages. Asexual parasite densities (per µL)
were calculated by establishing the ratio of parasites to
white blood cells and then multiplying the parasite
count by 8000, the average white cell count per µL of
blood.
Malaria transmission in Dielmo is intense and peren-
nial. We conducted a cross-sectional survey to estimate
the prevalence of symptoms related to allergic diseases
among 175 children aged from 1 month to 14 years old
who were born during the malaria research programme.
Both the longitudinal and cross-sectional surveys were
approved by the Ministry of Health of Senegal.
Informed consent of the volunteers is renewed every
year. More specifically for the cross-sectional survey, after
informing about the procedures and the purpose of the
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study, written informed consent was obtained from
parents or guardians of children either by signature or
by thumbprint on a voluntary consent form written in
both French and Wolof, the main local language.
Consent was obtained in the presence of the school dir-
ector, an independent witness.
The family structure (pedigree) was available after a
demographic census performed for every volunteer at
his adhesion in the project. A verbal interview of
mothers or key representatives of the household was
used to obtain information on genetic relationships
between studied individuals, their children, their parents
and to identify genetic links among the population. The
total pedigree comprised 828 individuals, including
absent or dead relatives, composed of 10 independent
families that can be subdivided into 206 nuclear families
(father–mother couples with at least one child) with an
average of 3.6 children each. Genetically related nuclear
families occur because of multiple marriages and mar-
riages among related individuals. Previous typing with
microsatellites has enabled the construction of a pedi-
gree based on Identity-by-Descent using MERLIN.20 28
The mean coefficient of inbreeding is 0.0008. Newborns
since this original genetic analysis were added to the
family of the parents in question. The 143 children, with
allergy and malaria data, belonged to 61 nuclear fam-
ilies and comprised 30 singletons, 102 siblings and 11
half-sibs (yielding 55 half-sib pairs). The mean genetic
relatedness (by pedigree) of the 143 children is 0.0114
(range: 0.0013–0.022).
P falciparum clinical episodes
P falciparum malaria clinical episode phenotypes ana-
lysed were: (1) clinical P falciparum infections treated
with antimalarial therapy and (2) the highest parasite
density during the P falciparum clinical episode. A clin-
ical P falciparum episode was defined as a clinical presen-
tation with fever (axillary temperature ≥37.5°C) and/or
other clinical signs suggestive of malaria associated with
a thick blood smear positive for P falciparum and that
was treated with antimalarial therapy. Repeated clinical
malaria presentations within 15 consecutive days were
not considered to be independent and were excluded
from the analyses, unless there was a negative thick
blood smear between two clinical presentations. We also
excluded observations in any trimester for which the
individual was not present for at least one-third of the
time.
We calculated the quarterly incidence rate of clinical
P falciparum episodes in children below the age of
15 years as the ratio of the total number of clinical P fal-
ciparum episodes during the trimester divided by the
total number of person-trimesters surveyed. Incidence
rate is expressed as cases per 100 person-trimesters (see
online supplementary figure S1). This rate was used in
the analysis to approximate the force of infection
(exposure level) within the targeted population at the
time of a given clinical P falciparum episode.
The total number of clinical presentations per trimes-
ter that were not attributable to P falciparum was tabu-
lated. Repeated non-malaria presentations within seven
consecutive days were not considered to be independent
and were excluded.
Allergic diseases and atopic status
The International Study of Asthma and Allergies in
Childhood (ISAAC) diagnostic criteria have been shown
to be reproducible, adequate and able to discriminate
children with allergic diseases in different areas of the
world.2 The standardised ISAAC questionnaire originally
written in English was translated into French in compli-
ance with ISAAC guidelines29 adapting it to the usual
local customs following advice from local clinicians and
paediatric allergologists (acknowledgements and see
online supplementary technical appendix). The
adequacy and reliability of the translated questionnaire
had been previously confirmed by a pilot study on 30
randomly selected children in the same community. The
questionnaire was completed by specially trained health
workers during an oral interview conducted in Wolof
with children and their mothers or guardians.
To assess the prevalence of allergic diseases in chil-
dren, we used the positive and negative predictive values
of the ISAAC questionnaire diagnosis criteria developed
for subtropical countries.30 Each question was scored
according to the medical diagnosis of paediatricians and
paediatric allergologists. Positive or negative answers
were thus graded on the basis of symptom sensitivity,
specificity, frequency, location or early onset. For each
allergic disease, three categories of symptom severity,
severe, moderate and none, were defined as follows:
Asthma—severe symptoms if the child had ‘wheezing or
whistling in the chest before the age of two years’ and
‘more than three times’ or severe enough to ‘limit his/
her speech’; moderate symptoms if the child had ‘wheez-
ing or whistling in the chest before the age of two years’
and ‘in the past 12 months’; and none otherwise.
Allergic rhinoconjunctivitis—severe symptoms if the child
had ‘sneezing, runny or stuffy nose in the past
12 months’ and ‘more than five times a year’ and ‘itchy,
watery eyes or tropical endemic limboconjunctivitis
(TELC) in the past 12 months’; moderate symptoms if the
child had ‘sneezing, runny or stuffy nose in the past
12 months’, and ‘itchy, watery eyes or TELC in the past
12 months’ and none otherwise.
Atopic dermatitis—severe symptoms if the child had ‘scaly
or exudating, crusted and pruritic patches in the past
12 months’ and ‘affecting any of the following character-
istic areas: face, around the ears or eyes, folds of armpits
or elbows or groin, behind the knees, under the but-
tocks’ and ‘onset of symptoms before the age of 2 years’;
moderate symptoms if the child had ‘scaly or exudating,
crusted and pruritic patches in the past 12 months’ and
‘affecting any of characteristic areas (see above) ’, and
‘onset of symptoms before the age of 4 years’ and none
otherwise.
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The inter-relationships between variables reflecting
the severity of symptoms of the three allergic diseases
were used to identify children at high risk of atopy. The
high probability group was defined by the prevalence of at
least one of any severe symptoms or two of any moderate
symptoms. The probable group was defined as those with
moderate symptoms from one of the three allergic dis-
eases and remaining children were classified in the
unlikely group.
Helminths
Helminthic infections are common in this region and
are known to modify the clinical course and outcome of
both allergic diseases and malaria.31 32 We therefore
carried out a helminth survey for 91 individuals present
during the cross-sectional survey. Diagnosis was per-
formed by stool examination by microscope and by the
Kato technique to search for the presence of Ascaris lum-
bricoides, hookworms (Ancylostoma duodenale and Necator
americanus), whipworm (Trichuris trichiuria), Schistosoma
mansoni and Strongyloides stercoralis. Examination for pin-
worms (Enterobius vermicularis) was performed by the
anal scotch-test. An antihelminthic treatment was pro-
posed for all infested individuals.
IgE titres
Specific IgE titres were measured by ELISA as previously
described.33 A panel of allergens of potential pertinence
to the three classes of allergy was used: (1) salivary gland
extracts (SGE) of two mosquito species present in the
study cohorts, Aedes aegypti and Anopheles gambiae sensu
stricto and (2) P falciparum parasite extract were prepared
as previously described31; (3) House dust mite spp.
Dermatophagoides farinae and Dermatophagoides pteronyssi-
nus; (4) a mix of pollen allergens from five ubiquitous
graminae spp. (Cock’s-foot (Dactylis glomerata), Timothy
grass (Phleum pratense), Sweet Vernal grass (Anthoxanthum
odoratum), Perennial ryegrass (Lolium perenne), Kentucky
Bluegrass (Poa pratensis)) (all from Stallergenes, France).
Statistical analysis
Statistical analyses were performed using R V.2.12.0 (The
R Foundation for Statistical Computing, Vienna,
Austria). To address the effect of allergic status on the
risk of clinical P falciparum episodes, we performed
Generalised Linear Mixed Models (GLMM) extended to
pedigree data using the pedigreemm package for R to
account for the non-independence of individuals
because of family relationships, shared house and for
repeated measures from the same individual (see online
supplementary technical appendix). Correlated individ-
ual effects due to familial relationships were taken into
account by using the pedigree-based genetic relatedness
matrix that contains the genetic covariance among all
pairs of individuals in the study cohort and is calculated
using the pedigree information.34 Shared house and
repeated measures from the same individual were mod-
elled as random effects. All random effects were
assumed to be normally distributed, and conditional on
these random effects, the dependent variable had: (1) a
Binomial distribution when the studied phenotype was
the occurrence of a clinical P falciparum episode treated
with antimalarial therapy during a trimester, (2) a
Gaussian distribution when the studied phenotype was
the logarithm of the maximum parasite density during a
given clinical P falciparum episode and (3) a Poisson dis-
tribution when the studied phenotype was the number
of non-malaria episodes per trimester. The effects of
allergy disease classes on these dependent variables were
modelled as fixed effects. Allergy classes were reduced
to two levels, severe or moderate vs none for analyses of
asthma, atopic dermatitis and allergic rhinoconjunctivitis
and high probability vs probable and unlikely for atopic ten-
dency. Covariables included sickle cell trait33 gender,
number of days present on site during the trimester, tri-
mestrial incidence of P falciparum and age. Age was ini-
tially analysed as a continuous covariate. To assess the
age-specific effect of allergy, age was categorised into two
levels (<3.5 years of age and ≥3.5 years of age, based on
the age of peak clinical incidence) and allergy class was
nested within age class. The age threshold was varied
from 1.5 to 5.5 years of age and the data reanalysed to
assess at which age there was the strongest effect. The
association of allergy classes with IgE levels was analysed
by Box-Cox transforming the data and fitting a GLMM
with a normal distribution.
RESULTS
Of the 205 eligible children aged under 15 years involved
in the family-based longitudinal study, 175 (85.4%) parti-
cipated in the cross-sectional survey to assess the preva-
lence of related symptoms of allergic diseases. All eligible
children present at the time of the survey were included;
no explicit refusal to participate was recorded. The study
cohort was aged from 1 month to 14 years 11 months.
The sex-ratio (male/female) was 0.94.
From 1994 until 2008, 143 of the children participating
in the cross-sectional survey were present for at least
31 days in any trimester during the study period generat-
ing a total of 3093 person-trimesters of presence (see
online supplementary table S1). There were 2065 treated
P falciparum clinical episodes (per individual: median 11,
range 0–47; see online supplementary table S2). The age
peak of incidence of P falciparum episodes occurred at
3–4 years of age (figure 1). There were 1868 non-malaria
episodes (median 12, range 0–37) (see online supple-
mentary table S2). These non-malaria clinical presenta-
tions were associated with headache (38%), chills (32%),
cough (13%), vomiting (11%) and diarrhoea (6%).
The prevalence of moderate or severe asthma symp-
toms was respectively 2.3% and 10.3% (table 1). The
prevalence of moderate or severe allergic rhinoconjuncti-
vitis symptoms was respectively 6.3% and 10.3%. The
prevalence of moderate or severe atopic dermatitis symp-
toms was respectively 6.3% and 2.9%. On the basis of
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symptom severity, an atopic tendency was estimated to be
unlikely for 68%, probable for 9.1% and highly probable
for 22.9% of the 175 children. The frequency of each
allergy class in children for whom malaria data were avail-
able is shown in online supplementary table S1.
The risk of treated clinical P falciparum infections was
higher for children with high probability of atopy (OR
1.65; 95% CIs 1.20 to 2.26; p=0.002; table 2), after adjust-
ing for age, sickle-cell trait and the exposure level.
Gender was not found to be significant. Analysing the
impact of atopy in children younger and older than the
peak age of clinical incidence (3–4 years old) revealed
that atopy increased the risk of P falciparum episodes in
children at an age greater than 3.5 years (OR 2.02, 1.39–
2.93; p=2×10–4), but not in children of age prior to the
peak clinical incidence (OR 1.38, 0.92 to 2.08; p=0.124;
table 2). This increased risk resulted in an ever increas-
ing cumulative number of P falciparum episodes with age
beyond that of peak clinical incidence (figure 2; see
online supplementary figure S2 for model predictions
for comparison).
Analysis by allergy category revealed that asthma (severe
or moderate) increases the risk of P falciparum episodes
(OR 2.12; 1.46 to 3.08; p=8×10−5) and this again only in
children of age greater than 3.5 years old (OR 2.33; 1.50
to 3.61; p=1.5×10−4). Atopic dermatitis increased the risk
of clinical malaria in children older (OR 3.15; 1.56 to 6.33;
p=1.3×10−3) but not younger than 3.5 years of age
(table 2). Allergic rhinoconjunctivitis was not associated
with increased risk of clinical malaria at any age (table 2).
The impact of atopy, asthma and atopic dermatitis can be
clearly seen in the ever-increasing number of cumulative
P falciparum episodes beyond the age of the onset of
clinical immunity in the population, 3.5 years of age
(figure 2). There is no difference in the number of clinical
malaria episodes prior to this age in individuals with or
without an allergic condition. Analysis using different age
thresholds (from 1.5 to 5.5 years of age) revealed similar
OR for thresholds of 2.5, 3.5 and 4.5 years of age. The
maximum OR for increased malaria occurred in children
older than 4.5 years of age and with atopy or atopic derma-
titis, whereas for the asthma group it occurred in children
after 3.5 years of age (see online supplementary table S3).
There was no impact of any allergic disease on the
number of non-malaria episodes by trimester (see
online supplementary table S4).
The impact of atopy, asthma and atopic dermatitis on
the maximum P falciparum parasite density during a given
clinical malaria episode mirrored that of the risk of P fal-
ciparum episodes. Parasite density was significantly higher
for children with allergic disease older than 3.5 years of
age (table 3 and see online supplementary figure S3 for
residuals of the fitted model). As the log-transformed
data were left skewed, we additionally analysed using
Box-Cox transformation and probit normalisation of the
data. The results were qualitatively the same (see online
supplementary text and figures S4–S8). Allergic rhino-
conjunctivitis had no impact on the parasite density
(table 3). Analysis using different age thresholds yielded
similar qualitative conclusions as seen with the number of
clinical episodes (see online supplementary table S3).
Individuals with moderate or severe symptoms of
atopic dermatitis had significantly higher specific IgE
Table 1 Classification of asthma, allergic
rhinoconjunctivitis, atopic dermatitis and overall Atopic
status according to International Study of Asthma and
Allergies in Childhood questionnaire in children aged 0–14
from a malaria birth cohort




None 153 (73/80) 87.43 125 (59/66)
Moderate 4 (1/3) 2.29 4 (1/3)
Severe 18 (6/12) 10.29 14 (4/10)
Rhinoconjunctivitis symptoms
None 146 (64/82) 83.43 120 (52/68)
Moderate 11 (8/3) 6.29 9 (6/3)
Severe 18 (6/12) 10.29 14 (6/8)
Atopic dermatitis symptoms
None 159 (75/84) 90.86 128 (60/68)
Moderate 11 (1/10) 6.29 11 (1/10)
Severe 5 (4/1) 2.86 4 (3/1)
Atopic tendency
Unlikely 119 (56/63) 68.00 97 (46/51)
Probable 16 (8/8) 9.14 14 (6/8)
Highly probable 40 (16/24) 22.86 32 (12/20)
N is total number of children examined and n-malaria represents
those for whom malaria data were recorded. F is the number of
females and M the number of males.
Figure 1 Annual incidence rate of clinical Plasmodium
falciparum episodes per 100 children (bold line). In order to
overcome the fluctuations of the annual incidence rate, we fit
second (dotted line), third (dashed line) and fourth (solid line)
degree polynomial trend lines to the data (bold line). The
corresponding R2 values are 0.70, 0.91 and 0.99,
respectively, indicating an accurate fit for third and fourth
order polynomials. The inflexion on these two trend lines
indicates the onset of acquisition of clinical immunity at
approximately 3–4 years of age.
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titres against A aegypti (p=0.004) and A gambiae SGE
(p<0.001). There were no detectable specific anti-P fal-
ciparum IgE. Individuals with moderate or severe symp-
toms of allergic rhinoconjunctivitis did not have
significantly higher IgE titres against the tested graminae
(p=0.28), although titres decreased with age (p=0.035).
There was also no effect of asthma on IgE titres against
the house dust mite spp. tested (D farinae p=0.60 and
D pteronyssinus p=0.27).
Only five individuals were infested with helminths
(two Ancylostoma, one Strongyloides, one Trichuris and one
Enterobius).
Figure 2 Mean cumulative
number of Plasmodium
falciparum clinical episodes with
age for the (A) asthma, (B)
rhinoconjunctivitis and (C) atopic
dermatitis classes and overall
atopy class (D) (bold lines)
compared with individuals without
symptoms of each respective
allergy type (thin lines). In all
cases moderate and severe
classes are combined and
compared with individuals without
allergy symptoms. Note there are
no children older than 11 years of
age with atopic dermatitis.
Table 2 Impact of allergy status on risk of Plasmodium falciparum clinical episodes
Age groups (3.5 years) aOR
95% CI
p ValueLower Upper
Atopy Both 1.65 1.20 2.26 2.0×10−3
<3.5 1.38 0.92 2.08 0.124
≥3.5 2.02 1.39 2.93 2.1×10−4
Asthma Both 2.12 1.46 3.08 8.0×10−5
<3.5 1.50 0.90 2.50 0.122
≥3.5 2.33 1.50 3.61 1.5×10−4
Atopic dermatitis Both 1.05 0.65 1.70 0.842
<3.5 0.84 0.49 1.46 0.539
≥3.5 3.15 1.56 6.33 1.3×10−3
Rhinoconjunctivitis Both 0.96 0.65 1.41 0.818
<3.5 1.05 0.64 1.72 0.853
≥3.5 0.95 0.60 1.52 0.834
Age ≥3.5 0.48 0.40 0.57 2.7×10−15
Trimestrial incidence 1.01 1.00 1.01 1.8×10−6
HbAS 0.24 0.12 0.47 3.7×10−5
Shown are the p values and adjusted ORs with 95% CIs calculated from the mixed-model analyses. Values for the covariables age
(≥3.5 years of age compared with <3.5 years of age), trimestrial incidence of P falciparum clinical episodes and HbAS (β-globin sickle-cell
trait; AS compared with AA) are those from the Asthma model analysis. For clarity significant covariables are shown in bold.




Establishing the allergic status of children up to the age
of 15 years followed for malaria since birth, revealed an
association of asthma and atopic dermatitis with suscepti-
bility to clinical P falciparum episodes. Importantly the
increase in risk of malaria associated with these allergic
conditions occurred after the peak clinical incidence of
disease in the population, suggesting that they delay the
development of clinical immunity to malaria.
Strengths and weaknesses of the study
The major strength of this study is the complete knowl-
edge of the number of clinical P falciparum malaria epi-
sodes each individual has had since birth and the
exposure level per trimester over the 15 years covering
the birth cohort. No other study has such detailed infor-
mation for such a length of time. The major weakness of
the study is the relatively small sample size, which would
have reduced power to detect an association. In addition,
although allergy diagnosis for children under 2 years of
age is not considered reliable, there were only 15 indivi-
duals under 2 at the time of the allergy study of the 143
for whom malaria and allergy data were available.
Meaning of the study
Under intense malaria transmission, after repeated
exposure to the parasite, children develop a clinical
immunity35 whereby they tolerate elevated parasite
densities without showing clinical symptoms. In this
cohort, the population mean onset of clinical immunity
occurred at 3–4 years of age. Although clinical immunity
is accompanied by a reduction in parasite density, effec-
tive antiparasite immunity develops much more slowly36
with individuals achieving a state of premunition,
whereby they maintain low-grade parasite densities in an
asymptomatic state.37 We show here that children with
clinically defined asthma or atopic dermatitis have an
increased risk of presenting with P falciparum malaria epi-
sodes requiring treatment once passing the age of peak
clinical incidence. They also had higher parasite density
during clinical episodes, suggesting a reduced ability to
control parasite replication. The observed increase in
clinical incidence of malaria in patients with asthma or
atopic dermatitis is not likely to be the result of increased
frailty of such individuals; these individuals did not come
more frequently to the clinic with non-malaria symptoms.
Our previous genome linkage study identifying chromo-
somal regions20 associated with malaria that overlap with
those previously shown to be linked to asthma/atopy sug-
gests that there may be a shared genetic basis to these
pathologies rather than any causative effect of one on the
other. This is consistent with the increased susceptibility
to malaria of mouse atopic models.23
Comparison with other studies
A previous study in Ethiopia (East Africa) found that a
history of malaria (yes/no) increased risk of atopic
Table 3 Impact of allergy status on the maximum Plasmodium falciparum parasite density during a clinical malaria episode
Allergic condition Age groups Allergic status (no/yes) Mean parasite density SEM p Value
Atopy Both N 76.3 13.8
Y 131.0 36.4 0.0158
<3.5 N 114.3 23.7
Y 171.1 56.0 0.148
≥3.5 N 48.4 9.8
Y 114.8 37.1 9.5×10−4
Asthma Both N 78.1 14.4
Y 148.5 44.3 3.8×10−3
<3.5 N 114.8 24.3
Y 171.9 74.5 0.167
≥3.5 N 51.3 9.7
Y 105.3 41.0 6.2×10−3
Atopic dermatitis Both N 82.6 15.0
Y 93.9 38.9 0.605
<3.5 N 122.6 25.5
Y 133.9 63.5 0.425
≥3.5 N 52.3 11.0
Y 135.4 70.7 0.014
Rhinoconjunctivitis Both N 81.5 14.8
Y 111.4 39.0 0.570
<3.5 N 118.8 25.1
Y 166.3 69.9 0.537
≥3.5 N 54.6 11.3
Y 80.9 33.7 0.327
Shown are the back-transformed mean parasite densities per microlitre and SE measurements (SEM) estimated from the generalised linear
mixed model analyses after taking into account the other covariables. Significantly different effects are shown in bold for clarity.
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dermatitis in 306 cases compared with 426 controls as
characterised using the ISAAC questionnaire.22 The only
other epidemiological study that has previously exam-
ined the link between malaria and atopy38 also inter-
preted the result from the perspective of the impact of
malaria on atopy. They examined the reinfection rate
with P falciparum over a 5-year period in 91 children who
were subsequently classified as atopic or not using skin
prick tests (SPT) with house dust mite antigen. Their
conclusion was that, as with measles13 and tuberculosis15
malaria infection reduces atopy. However, the study
lacked previous infection data since birth of the partici-
pating individuals and focused on atopy as determined
by SPT against a single allergen. The case-control study
of atopic dermatitis risk factors cited above found no
overall association between allergen skin sensitisation
and atopic dermatitis. We also found no evidence of
increased IgE titres against house dust mites in the asth-
matic or atopic dermatitis groups or against grass pollen
in individuals with allergic rhinoconjunctivitis. Such dif-
ferences likely reflect the different IgE reactivity profiles
due to differences in allergen exposure in Africa.39
There was no evidence of antiparasite IgE in this cohort
of children. We previously showed that circulating anti-
parasite IgE titres were strongly positively correlated with
antimosquito saliva IgE, but became undetectable follow-
ing malaria exposure, potentially being bound to
effector cells.33 Only mosquito saliva, a known major
local allergen, induced a specific IgE response at signifi-
cantly higher titres in individuals with atopic dermatitis.
Although the immune effectors of clinical immunity
are still poorly defined, there is strong evidence that
acquired antiparasite immunity is IgG-dependent8 and
cytophilic immunoglobulins (IgG1 and IgG3), which are
capable of eliminating the parasites by opsonisation
and/or by antibody dependent cellular immunity play
an important role in premunition.37 The higher parasite
density during symptomatic episodes observed in the
asthma group suggests impaired development of
acquired immunity. Impaired acquisition of immunity to
malaria in children with asthma or atopic dermatitis may
stem from their imbalanced Th1/Th2 response. Indeed,
an atopic state may generate a tendency to develop a
Th2 type immune response to P falciparum. Dendritic
cells that are oriented to a Th2 phenotype are more sus-
ceptible to orient the acquired immune response
towards a Th2 profile.40 Orientation of the immune
response towards a Th2 profile by asthma or atopic
dermatitis would result in a poor Th1 response (and
hence development of protective IgG), considered to be
the dominant arm of the immune response enabling
resistance to infectious disease in children.41
Many studies have revealed an important role of hista-
mine, a key downstream effector molecule in allergic
reaction, in the outcome of a malaria parasite infec-
tion.24–26 42–45 Moreover, reports indicate that compo-
nents of the innate immune system, including
eosinophils, basophils and MCs, could play important
roles in the pathogenesis of malaria.42 Increased levels
of histamine in plasma and tissue, derived from baso-
phils and MCs, notably following stimulation by IgE
through the high affinity receptor FcɛR1, are associated
with the severity of disease in humans infected with
P falciparum and in animal malaria models.25 26
Chlorpheniramine, a HR1 agonist reversed resistance to
chloroquine and amodiaquine both in vivo and in
vitro.43 Moreover, astemizole, another HR1 agonist, was
identified as an antimalarial agent in a clinical drug
library screen.44 Finally, P falciparum produces transla-
tionally controlled tumour protein, which is a homo-
logue of the mammalian histamine-releasing factor that
causes histamine release from human basophils.45
Further research
Our results provide the first birth cohort study addres-
sing the link between malaria and allergic diseases. They
contribute to a growing body of evidence that the path-
ologies are related. ISAAC has revealed a steady but sig-
nificant increase in prevalence rates of asthma and
allergic diseases in Africa. While the majority of studies
have focused on large cities, there is increasing urbanisa-
tion throughout Africa, as well as improved access to
primary healthcare in many areas. A key concern for
ISAAC is the extent to which such societal evolution will
result in an increase in allergic diseases. Increased
urbanisation in sub-Saharan Africa is changing the epi-
demiology of malaria and although resulting in a
decrease in risk, will result in more severe clinical
malaria in older individuals.46 47 Moreover, a large con-
sumption of antimalarial drugs in the urban areas pro-
vides substantial drug pressure fostering the selection of
drug-resistant parasites. Despite the encouraging recent
decrease in malaria incidence rates, even in rural areas,
an additional significant concern is the extent to which
such an increase in allergy will exacerbate the burden of
malaria. Given the demonstrated antiparasitic effect of
antihistamines,48 administration of antihistamines to
atopic children will likely reduce the burden of clinical
malaria in these children, increase the efficacy of first-
line treatment antimalarials49 and alleviate the non-
infectious consequences of atopy. Clinical intervention
studies should be envisaged.
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